COSMIC: a regimen of intensity modulated radiation therapy plus dose-escalated, raster-scanned carbon ion boost for malignant salivary gland tumors : results of the prospective phase 2 trial / Alexandra D. Jensen, MD, MSc, Anna V. Nikoghosyan, MD, Karen Lossner, Thomas Haberer, PhD, Oliver Jäkel, PhD, Marc W. Münter, MD, and Jürgen Debus, MD, PhD
Purpose - To investigate the effect of intensity modulated radiation therapy (IMRT) and dose-escalated carbon ion (C12) therapy in adenoid cystic carcinoma (ACC) and other malignant salivary gland tumors (MSGTs) of the head and neck. - Patients and Methods - COSMIC (combined treatment of malignant salivary gland tumors with intensity modulated radiation therapy and carbon ions) is a prospective phase 2 trial of 24 Gy(RBE) C12 followed by 50 Gy IMRT in patients with pathologically confirmed MSGT. The primary endpoint is mucositis Common Terminology Criteria grade 3; the secondary endpoints are locoregional control (LC), progression-free survival (PFS), overall survival (OS), and toxicity. Toxicity was scored according to the Common Terminology Criteria for Adverse Events version 3; treatment response was scored according to Response Evaluation Criteria in Solid Tumors 1.1. - Results - Between July 2010 and August 2011, 54 patients were accrued, and 53 were available for evaluation. The median follow-up time was 42 months; patients with microscopically incomplete resections (R1, n=20), gross residual disease (R2, n=17), and inoperable disease (n=16) were included. Eighty-nine percent of patients had ACC, and 57% had T4 tumors. The most common primary sites were paranasal sinus (34%), submandibular gland, and palate. At the completion of radiation therapy, 26% of patients experienced grade 3 mucositis, and 20 patients reported adverse events of the ear (38%). The most common observed late effects were grade 1 xerostomia (49%), hearing impairment (25%, 2% ipsilateral hearing loss), and adverse events of the eye (20%), but no visual impairment or loss of vision. Grade 1 central nervous system necrosis occurred in 6%, and 1 grade 4 ICA hemorrhage without neurologic sequelae. The best response was 54% (complete response/partial remission). At 3 years, the LC, PFS, and OS were 81.9%, 57.9%, and 78.4%, respectively. No difference was found regarding resection status. The most common site of failure was distant (55%). Local relapse was predominantly in field (79%). - Conclusion - Treatment was tolerated, with moderate acute and late toxicity. The LC at 3 years was promising. No significant difference could be shown regarding resection status; hence, extensive and mutilating surgical procedures should be rediscussed. Further dose escalation may be limited in view of potential vascular adverse events..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
19 May 2015 2015 |
---|---|
Erschienen: |
19 May 2015 |
Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
---|---|
Enthalten in: |
International journal of radiation oncology, biology, physics - 93(2015), 1, Seite 37-46 |
Sprache: |
Englisch |
---|
Weiterer Titel: |
two |
---|
Beteiligte Personen: |
Jensen, Alexandra, 1976- [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Gesehen am 19.06.2020 |
---|
Umfang: |
10 |
---|
doi: |
10.1016/j.ijrobp.2015.05.013 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
1700169599 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | 1700169599 | ||
003 | DE-627 | ||
005 | 20240406193211.0 | ||
007 | cr uuu---uuuuu | ||
008 | 200608s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ijrobp.2015.05.013 |2 doi | |
035 | |a (DE-627)1700169599 | ||
035 | |a (DE-599)KXP1700169599 | ||
035 | |a (OCoLC)1341328416 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
100 | 1 | |a Jensen, Alexandra |d 1976- |e verfasserin |0 (DE-588)136129552 |0 (DE-627)577179020 |0 (DE-576)284704687 |4 aut | |
245 | 1 | 0 | |a COSMIC: a regimen of intensity modulated radiation therapy plus dose-escalated, raster-scanned carbon ion boost for malignant salivary gland tumors |b results of the prospective phase 2 trial |c Alexandra D. Jensen, MD, MSc, Anna V. Nikoghosyan, MD, Karen Lossner, Thomas Haberer, PhD, Oliver Jäkel, PhD, Marc W. Münter, MD, and Jürgen Debus, MD, PhD |
246 | 3 | 0 | |a two |
264 | 1 | |c 19 May 2015 | |
300 | |a 10 | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Gesehen am 19.06.2020 | ||
520 | |a Purpose - To investigate the effect of intensity modulated radiation therapy (IMRT) and dose-escalated carbon ion (C12) therapy in adenoid cystic carcinoma (ACC) and other malignant salivary gland tumors (MSGTs) of the head and neck. - Patients and Methods - COSMIC (combined treatment of malignant salivary gland tumors with intensity modulated radiation therapy and carbon ions) is a prospective phase 2 trial of 24 Gy(RBE) C12 followed by 50 Gy IMRT in patients with pathologically confirmed MSGT. The primary endpoint is mucositis Common Terminology Criteria grade 3; the secondary endpoints are locoregional control (LC), progression-free survival (PFS), overall survival (OS), and toxicity. Toxicity was scored according to the Common Terminology Criteria for Adverse Events version 3; treatment response was scored according to Response Evaluation Criteria in Solid Tumors 1.1. - Results - Between July 2010 and August 2011, 54 patients were accrued, and 53 were available for evaluation. The median follow-up time was 42 months; patients with microscopically incomplete resections (R1, n=20), gross residual disease (R2, n=17), and inoperable disease (n=16) were included. Eighty-nine percent of patients had ACC, and 57% had T4 tumors. The most common primary sites were paranasal sinus (34%), submandibular gland, and palate. At the completion of radiation therapy, 26% of patients experienced grade 3 mucositis, and 20 patients reported adverse events of the ear (38%). The most common observed late effects were grade 1 xerostomia (49%), hearing impairment (25%, 2% ipsilateral hearing loss), and adverse events of the eye (20%), but no visual impairment or loss of vision. Grade 1 central nervous system necrosis occurred in 6%, and 1 grade 4 ICA hemorrhage without neurologic sequelae. The best response was 54% (complete response/partial remission). At 3 years, the LC, PFS, and OS were 81.9%, 57.9%, and 78.4%, respectively. No difference was found regarding resection status. The most common site of failure was distant (55%). Local relapse was predominantly in field (79%). - Conclusion - Treatment was tolerated, with moderate acute and late toxicity. The LC at 3 years was promising. No significant difference could be shown regarding resection status; hence, extensive and mutilating surgical procedures should be rediscussed. Further dose escalation may be limited in view of potential vascular adverse events. | ||
700 | 1 | |a Nikoghosyan, Anna |d 1974- |e verfasserin |0 (DE-588)129613355 |0 (DE-627)474758192 |0 (DE-576)297749196 |4 aut | |
700 | 1 | |a Lossner, Karen |e verfasserin |0 (DE-588)1165154366 |0 (DE-627)1029319375 |0 (DE-576)510270581 |4 aut | |
700 | 1 | |a Haberer, Thomas |d 1960- |e verfasserin |0 (DE-588)123579198 |0 (DE-627)706353714 |0 (DE-576)214902188 |4 aut | |
700 | 1 | |a Jäkel, Oliver |d 1964- |e verfasserin |0 (DE-588)1050056302 |0 (DE-627)783260709 |0 (DE-576)404358705 |4 aut | |
700 | 1 | |a Münter, Marc |d 1972- |e verfasserin |0 (DE-588)121295591 |0 (DE-627)705363104 |0 (DE-576)292633645 |4 aut | |
700 | 1 | |a Debus, Jürgen |d 1964- |e verfasserin |0 (DE-588)1022671421 |0 (DE-627)717025780 |0 (DE-576)365774944 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of radiation oncology, biology, physics |d Amsterdam [u.a.] : Elsevier Science, 1975 |g 93(2015), 1, Seite 37-46 |h Online-Ressource |w (DE-627)306659662 |w (DE-600)1500486-7 |w (DE-576)081986319 |x 1879-355X |7 nnns |
773 | 1 | 8 | |g volume:93 |g year:2015 |g number:1 |g pages:37-46 |g extent:10 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.ijrobp.2015.05.013 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0360301615005179 |x Verlag |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ILN_2013 | ||
912 | |a ISIL_DE-16-250 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2070 | ||
912 | |a GBV_ILN_2086 | ||
912 | |a GBV_ILN_2098 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2116 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2119 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
951 | |a AR | ||
952 | |d 93 |j 2015 |e 1 |h 37-46 |g 10 | ||
980 | |2 2013 |1 01 |x DE-16-250 |b 3684345571 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 08-06-20 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2015 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_7 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_10 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1435776518 |a Jensen, Alexandra | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1513369962 |a Nikoghosyan, Anna | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416741399 |a Radiologische Universitätsklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_2 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s p |0 (DE-627)1580270646 |a Lossner, Karen | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s k |0 (DE-627)1416741399 |a Radiologische Universitätsklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 06 |s s |a pos_3 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s p |0 (DE-627)1450270395 |a Haberer, Thomas | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s k |0 (DE-627)1471139212 |a Heidelberger Ionenstrahltherapiezentrum (HIT) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 07 |s s |a pos_4 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s p |0 (DE-627)1474358551 |a Jäkel, Oliver | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s k |0 (DE-627)1471139212 |a Heidelberger Ionenstrahltherapiezentrum (HIT) | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 08 |s s |a pos_5 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s p |0 (DE-627)1435778219 |a Münter, Marc | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 09 |s s |a pos_6 | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s p |0 (DE-627)1435777980 |a Debus, Jürgen | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s k |0 (DE-627)1416741399 |a Radiologische Universitätsklinik | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |0 (DE-627)1410501914 |a Verfasser | ||
982 | |2 2013 |1 01 |x DE-16-250 |8 10 |s s |a pos_7 |